Home › Companies › MBX

MBX Biosciences

Market cap $2.64B 49.7M shares (10-Q, Nov 5, 2026) × $53.10 close Nov 17, 2026

Most recent annual filing: 2026-03-12

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. MBX 4291 Ph1 interim4Q 2026MBX 4291 Ph1 interim, 4Q 2026, material
  2. MBX 4291 Ph2 readout2027MBX 4291 Ph2 readout, 2027, notable
  3. Septerna SEP-479 readout1Q 2027Septerna SEP-479 readout, 1Q 2027, notable
  4. Amgen MariTide Ph3 readout2027Amgen MariTide Ph3 readout, 2027, notable
  5. MBX 5765 and 6180 trial2027MBX 5765 and 6180 trial, 2027, routine
  6. BridgeBio encaleret FDA decisionMay 8, 2027BridgeBio encaleret FDA decision, May 8, 2027, material
  7. Canvuparatide topline~About mid-2028 (estimate)Canvuparatide topline, ~About mid-2028 (estimate), thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

PEP

Precision Endocrine Peptide platform — proprietary peptide engineering and programmable prodrug technology combining multiple mechanisms of action, enhanced potency, improved stability and solubility, and fatty acylation for extended half-life; designed for once-monthly dosing with flattened, sustained exposure and improved tolerability; focus areas: endocrine and metabolic diseases including hypoparathyroidism and obesity

Targets: PTH, GLP-1 receptor, GIP receptor, GCGR, GLP-1, GIP, glucagon, DACRA, GCG, amylin receptor, calcitonin receptor, PTH1R

Discontinued (1)

Capital (as filed)

Cash
$162M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$320M Sep 30, 2026
Operating cash flow
−$34.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$482M cash, runway into 2029 per the deep dive of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on MBX Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch MBX Biosciences (MBX) - Scientific Deep Dive for Canvuparatide, MBX 4291 and Pipeline Products At ~$2.4B EV the stock already prices a Phase 3 win; canvuparatide has not been shown to beat Yorvipath on anything but injection frequency, there is no issued U.S. patent, and the obesity leg has no interpretable data yet.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (21)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)